We found no evidence to support a protective association between perinatal use of probiotics and doctor diagnosed asthma or childhood wheeze .
R and omised controlled trials to date have not yielded sufficient evidence to recommend probiotics for the primary prevention of these disorders .
OBJECTIVE To evaluate the association of probiotic supplementation during pregnancy or infancy with  childhood asthma and wheeze .
A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years
Using a double blind r and omized placebo‐controlled trial ( Australian New Zeal and Clinical Trials Registry : ACTRN12607000518460 ) , we have shown that in a high risk birth cohort , maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation until 2 years with Lactobacillus rhamnosus HN001 ( HN001 ) ( 6 × 109 cfu/day ) halved the cumulative prevalence of eczema by age 2 years . Bifidobacterium animalis subsp lactis HN019 ( HN019 ) ( 9 × 109 cfu/day ) had no effect
We found no evidence to support a protective association between perinatal use of probiotics and doctor diagnosed asthma or childhood wheeze .
R and omised controlled trials to date have not yielded sufficient evidence to recommend probiotics for the primary prevention of these disorders .
OBJECTIVE To evaluate the association of probiotic supplementation during pregnancy or infancy with  childhood asthma and wheeze .